Related Party Transactions |
3 Months Ended | ||
|---|---|---|---|
Mar. 31, 2026 | |||
| Related Party Transactions [Abstract] | |||
| Related Party Transactions |
The Company has entered into various research, development, license and supply agreements with PeriNess Ltd. (“PeriNess”), Serum Institute and Pharmsynthez, each a related party whose relationship has not materially changed from that disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 12, 2026, as amended on April 24, 2026. The Company has paid PeriNess approximately $0.3 million to date under this contract through March 31, 2026. As of March 31, 2026 and December 31, 2025, approximately $50,000 was recorded as an advanced payment and included in prepaid expenses and other current assets. In addition, approximately $9,000 and $8,000 was reflected in accounts payable on the March 31, 2026 and 2025 consolidated balance sheet, respectively. No amounts were incurred in connection with agreements with Serum Institute and Pharmsynthez during the three months ended March 31, 2026 and 2025.
During the first quarter of 2025, the Company entered into a Consulting Agreement with Dr. Dmitry Genkin, Chairman of our Board, to provide consulting services related to the Company’s DNase-based oncology program. This agreement was effective January 1, 2025 and the Company has paid Dr. Genkin approximately $0.5 million through March 31, 2026, of which approximately $30,000 was reflected within accounts payable as of both March 31, 2026 and December 31, 2025. Dr. Genkin does not receive any fees for his service as a member of the Board. |